Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

Rhea-AI Summary

Eledon (Nasdaq: ELDN) announced that updated data from an investigator-initiated islet transplant trial of tegoprubart in patients with type 1 diabetes will be presented at the American Diabetes Association 86th Scientific Sessions on June 7, 2026, in New Orleans.

The oral presentation, titled “Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation”, will be delivered by Piotr Witkowski, M.D., Ph.D. in Session “Immune Modulatory Strategies for Next-Generation Cell Therapies,” from 2:30 p.m. to 3:00 p.m. CT in Room 343 (Level 3).

AI-generated analysis. Not financial advice.

News Market Reaction – ELDN

-5.28%

2 alerts

-5.28% News Effect

-$16M Valuation Impact

$286.37M Market Cap

0.1x Rel. Volume

On the day this news was published, ELDN declined 5.28%, reflecting a notable negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $16M from the company's valuation, bringing the market cap to $286.37M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ADA session number: 86th Scientific Sessions Conference dates: June 5–9, 2026 Presentation date: June 7, 2026 +2 more

5 metrics

ADA session number 86th Scientific Sessions American Diabetes Association 2026 meeting

Conference dates June 5–9, 2026 ADA 2026 Scientific Sessions in New Orleans

Presentation date June 7, 2026 Oral presentation of tegoprubart islet transplant data

Presentation time 2:30–3:00 p.m. CT Scheduled oral session on June 7, 2026

Room number Room 343 (Level 3) Location of ADA oral presentation

Market Reality Check

Price: $3.41 Vol: Volume 613,710 is below t...

low vol

$3.41 Last Close

Volume Volume 613,710 is below the 20-day average of 1,117,950 (rel. volume 0.55). low

Technical Price $3.60 is trading above the 200-day MA of $2.67 and 21.74% below the 52-week high.

Peers on Argus

Peers show mixed moves: declines in MCRB (-2.14%) and CABA (-0.28%), gains in NK...

Peers show mixed moves: declines in MCRB (-2.14%) and CABA (-0.28%), gains in NKTX (+1.84%), AARD (+3.66%), and NVCT (+3.64%). This suggests ELDN’s -1.13% move is more stock-specific than sector-driven.

Historical Context

5 past events · Latest: May 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 20	Clinical data preview	Positive	+1.3%	Planned presentation of new Phase 2 BESTOW kidney transplant data at a conference.
May 13	Earnings and updates	Positive	+1.8%	Q1 2026 results with strong islet transplant outcomes and orphan designation details.
Mar 19	Full-year results	Positive	+1.1%	2025 results highlighting improved kidney eGFR and robust islet transplant efficacy data.
Mar 16	Islet trial update	Positive	+2.0%	Updated UChicago islet transplant data showing insulin independence and favorable safety.
Mar 10	Orphan designation	Positive	+0.0%	FDA Orphan Drug designation for liver transplant rejection prevention with plans for new trial.

Pattern Detected

Recent positive clinical and regulatory updates for tegoprubart have generally coincided with modestly positive price reactions.

Recent Company History

Over the past several months, Eledon has repeatedly highlighted progress for tegoprubart across transplantation indications. Updates included islet transplant data with insulin independence in type 1 diabetes, new long-term Phase 2 BESTOW kidney data, and multiple FDA Orphan Drug designations, including for liver transplantation. Earnings reports on Mar 19, 2026 and May 13, 2026 emphasized growing R&D investment and detailed favorable graft function outcomes. Today’s ADA presentation notice continues this pattern of showcasing tegoprubart data at major conferences.

Regulatory & Risk Context

Active S-3 Shelf · $500,000,000

Shelf Active

Active S-3 Shelf Registration 2026-05-01

$500,000,000 registered capacity

An effective S-3 shelf filed on 2026-05-01 permits Eledon to offer up to $500,000,000 in various securities, including an at-the-market program for up to $75,000,000 of common stock. No usage is reported yet, but the capacity provides flexibility for future capital raising.

Market Pulse Summary

The stock moved -5.3% in the session following this news. A negative reaction despite another confer...

Analysis

The stock moved -5.3% in the session following this news. A negative reaction despite another conference-focused update could fit a pattern where investors discount data reminders and focus on financing and execution risk. Recent filings detail continued net losses and an effective $500,000,000 shelf with a $75,000,000 ATM program, which may raise dilution concerns. Historically, prior tegoprubart news around Mar–May 2026 coincided with small gains, so a sharp decline would represent a departure from that behavior.

Key Terms

investigator-initiated, islet transplant, type 1 diabetes, anti-cd40l, +2 more

6 terms

investigator-initiated medical

"updated results from an investigator-initiated trial being conducted at the University of Chicago"

An investigator-initiated study is a research project started and run by a doctor, scientist, or academic institution rather than by a drug or device company; the investigator designs the study, enrolls patients, and often arranges funding or support. For investors, these studies can produce independent data that may strengthen or weaken a product’s prospects, like a customer-run test revealing real-world performance outside the maker’s control.

islet transplant medical

"investigator-initiated islet transplant trial of Tegoprubart in patients with Type 1 Diabetes"

A procedure that implants small clusters of insulin-producing cells (called islets) into a patient to restore the body’s natural ability to make insulin, most often used for type 1 diabetes. Investors care because successful islet transplants can create new medical products or services, alter long-term treatment costs and demand, and affect regulatory approvals and reimbursement — like replacing a faulty thermostat with a device that automatically keeps temperature in range.

type 1 diabetes medical

"islet transplant trial of Tegoprubart in patients with Type 1 Diabetes at American Diabetes Association"

An autoimmune condition in which the pancreas stops producing insulin, a hormone that lets the body use sugar for energy; without insulin people must manage blood sugar with injections, pumps, or other therapies. For investors, it matters because the lifelong need for medicines, devices, and monitoring creates steady demand, influences healthcare spending and reimbursement decisions, and drives clinical trials and regulatory activity in the diabetes treatment market.

anti-cd40l medical

"Presentation Title: Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation"

Anti-CD40L is a lab-made antibody designed to bind and block CD40 ligand, a protein on certain immune cells that helps drive inflammation and immune activation. For investors, drugs that target this pathway can reduce harmful immune responses in autoimmune disease, prevent organ-rejection after transplant, or modulate cancer immunity, so progress or safety issues in anti-CD40L programs can strongly affect a biotech’s value much like a key engine determining a car’s performance and reliability.

islet allotransplantation medical

"Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation"

Islet allotransplantation is a medical procedure that transfers insulin-producing cell clusters (islets) from a human donor into a patient to restore or improve the body’s ability to regulate blood sugar. For investors, it matters because successful transplants can reduce long-term treatment costs and change demand for insulin, drugs, medical devices, and cell-therapy markets; clinical trial results, regulatory approvals, and reimbursement decisions directly affect commercial potential.

cell therapies medical

"Session: Immune Modulatory Strategies for Next-Generation Cell Therapies"

Cell therapies are medical treatments that use living cells as the active medicine to repair, replace or reprogram damaged tissue or disease processes; the cells can come from the patient, a donor, or be made in a lab. For investors, they matter because they can offer long-lasting or curative effects unlike conventional drugs, but they also carry high research and manufacturing costs, complex regulation and scaling challenges—think of them as custom-built machines that can do remarkable work but are expensive and tricky to produce and deliver.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the American Diabetes Association 86th Scientific Sessions, taking place June 5-9, 2026, in New Orleans, Louisiana.

Details of the oral presentation are as follows:

Presentation Title: Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation
Session: Immune Modulatory Strategies for Next-Generation Cell Therapies
Date: Sunday, June 7, 2026
Time: 2:30 p.m. – 3:00 p.m. CT
Room: 343 (Level 3)

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com

Source: Eledon Pharmaceuticals

FAQ

What did Eledon (NASDAQ: ELDN) announce about tegoprubart at ADA 2026?

Eledon announced that updated data from an investigator-initiated islet transplant trial of tegoprubart in type 1 diabetes will be presented at the ADA 2026 Scientific Sessions. According to Eledon, this is an oral presentation within an immune modulation-focused session.

When is Eledon’s tegoprubart islet transplant trial data being presented at ADA 2026?

The updated tegoprubart islet transplant trial data will be presented on Sunday, June 7, 2026 from 2:30 p.m. to 3:00 p.m. CT. According to Eledon, the talk occurs during the ADA’s 86th Scientific Sessions in New Orleans.

What is the title of Eledon’s ADA 2026 presentation on tegoprubart (ELDN)?

The ADA 2026 presentation is titled “Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation.” According to Eledon, this oral presentation focuses on immune modulation strategies related to graft survival and function in islet allotransplantation for type 1 diabetes.

Who is presenting Eledon’s tegoprubart islet transplant data at ADA 2026?

The data will be presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine. According to Eledon, the trial is investigator-initiated and conducted at the University of Chicago Medicine Transplant Institute.

Where at the ADA 2026 Scientific Sessions will the ELDN tegoprubart data be presented?

The presentation will take place in Room 343 (Level 3) at the ADA 86th Scientific Sessions in New Orleans. According to Eledon, it is part of the session “Immune Modulatory Strategies for Next-Generation Cell Therapies.”

What session will feature Eledon’s tegoprubart islet transplant trial at ADA 2026?

The presentation is included in the session titled “Immune Modulatory Strategies for Next-Generation Cell Therapies.” According to Eledon, this session highlights approaches like anti-CD40L therapy aimed at improving graft survival and function in islet allotransplantation for type 1 diabetes.